IO Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	23.48	23.61	24.44	11.08	1.68	1.98
Research & Development	70.24	67.83	46.99	30.15	8.46	7.94
Operating Expenses	93.72	91.44	71.42	41.23	10.15	9.91
Operating Income	-93.72	-91.44	-71.42	-41.23	-10.15	-9.91
Interest Expense / Income	0	0	0.3	0.36	0.03	0.01
Other Expense / Income	-6.08	-6.21	-1.54	26.22	1.87	0.82
Pretax Income	-87.64	-85.23	-70.19	-67.81	-12.04	-10.74
Income Tax	0.86	0.85	1.27	0.07	0	0
Net Income	-88.5	-86.08	-71.46	-67.88	-12.04	-10.74
Preferred Dividends	0	0	0	7.11	2.55	1.77
Net Income Common	-88.5	-86.08	-71.46	-74.99	-14.59	-12.52
Shares Outstanding (Basic)	66	44	29	4	0	0
Shares Outstanding (Diluted)	66	44	29	4	0	0
Shares Change	128.63%	51.10%	564.62%	2346.74%	-	-
EPS (Basic)	-1.79	-1.98	-2.48	-17.30	-82.36	-70.64
EPS (Diluted)	-1.79	-1.98	-2.48	-17.30	-82.36	-70.64
Free Cash Flow	-82.17	-72.06	-60.42	-40.8	-9.96	-8.89
Free Cash Flow Per Share	-1.25	-1.66	-2.10	-9.41	-56.19	-50.17
EBITDA	-86.84	-84.48	-69.34	-67.45	-12.02	-10.74
Depreciation & Amortization	0.79	0.76	0.54	0	0	0
EBIT	-87.64	-85.23	-69.88	-67.45	-12.02	-10.74

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).